Proteasome Inhibitors Block DNA Repair and Radiosensitize Non-Small Cell Lung Cancer

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Cron, Kyle R ^a   Zhu, Kaya ^a   Kushwaha, Deepa S ^a   Hsieh, Grace ^a   Merzon, Dmitry ^a   Rameseder, Jonathan ^b   Chen, Clark C ^c   D'Andrea, Alan D ^a   Kozono, David ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; BRCA1 PROTEIN; FANCONI ANEMIA GROUP D2 PROTEIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME INHIBITOR; PROTEIN RAD1; SHORT HAIRPIN RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER RADIOTHERAPY; CONTROLLED STUDY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; FANCD2 GENE; GENE; GENE EXPRESSION; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; I KAPPA B ALPHA GENE; IONIZING RADIATION; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; OVERALL SURVIVAL; PSMA1 GENE; RAD1 GENE; RADIOSENSITIZATION; RNA INTERFERENCE; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

ANIMALS; BORONIC ACIDS; BRCA1 PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; COMBINED MODALITY THERAPY; DNA REPAIR; FANCONI ANEMIA COMPLEMENTATION GROUP D2 PROTEIN; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PROTEIN SUBUNITS; PYRAZINES; RAD51 RECOMBINASE; RADIATION, IONIZING; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84883543030     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073710     Document Type: Article

References (51)

1. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, et al. (2010) Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303: 1070-1076.
2. Ponn RB, Lo Cicero J, Daly BDT (2005) Surgical treatment of non-small cell lung cancer. In: Shields TW, Lo Cicero J, Ponn R, editors. General Thoracic Surgery. Philadelphia, PA: Lippincott Williams & Williams. 1548-1587.
3. Marks LB, Bentzen SM, Deasy JO, Kong FM, Bradley JD, et al. (2010) Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys 76: S70-76.
4. Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, et al. (2010) Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 28: 2181-2190.
5. Janne PA, Engelman JA, Johnson BE, (2005) Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 23: 3227-3234.
6. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693-1703.
7. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, et al. (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069-1075.
8. Weir BA, Woo MS, Getz G, Perner S, Ding L, et al. (2007) Characterizing the cancer genome in lung adenocarcinoma. Nature 450: 893-898.
9. Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, et al. (2008) Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 14: 822-827.
10. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, et al. (2001) Initial sequencing and analysis of the human genome. Nature 409: 860-921.
11. Szulc J, Wiznerowicz M, Sauvain MO, Trono D, Aebischer P, (2006) A versatile tool for conditional gene expression and knockdown. Nat Methods 3: 109-116.
12. Kahle KT, Kozono D, Ng K, Hsieh G, Zinn PO, et al. (2010) Functional genomics to explore cancer cell vulnerabilities. Neurosurg Focus 28: E5.
13. Steel GG, Peckham MJ, (1979) Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5: 85-91.
14. Ostashevsky JY, (1989) A model relating cell survival to DNA fragment loss and unrepaired double-strand breaks. Radiat Res 118: 437-466.
15. Rothkamm K, Kruger I, Thompson LH, Lobrich M, (2003) Pathways of DNA double-strand break repair during the mammalian cell cycle. Mol Cell Biol 23: 5706-5715.
16. Davies AM, Chansky K, Lara PN Jr, Gumerlock PH, Crowley J, et al. (2009) Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339). J Thorac Oncol 4: 87-92.
17. Li T, Ho L, Piperdi B, Elrafei T, Camacho FJ, et al. (2010) Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naive patients with advanced stage non-small cell lung cancer (NSCLC). Lung Cancer 68: 89-93.
18. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, et al. (2007) LKB1 modulates lung cancer differentiation and metastasis. Nature 448: 807-810.
19. Chen Z, Cheng K, Walton Z, Wang Y, Ebi H, et al. (2012) A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 483: 613-617.
20. Hanel W, Moll UM, (2012) Links between mutant p53 and genomic instability. J Cell Biochem 113: 433-439.
21. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, et al. (2009) A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137: 835-848.
22. Tanaka K, (2009) The proteasome: overview of structure and functions. Proc Jpn Acad Ser B Phys Biol Sci 85: 12-36.
23. Mortenson MM, Schlieman MG, Virudachalam S, Bold RJ, (2004) Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line. Cancer Chemother Pharmacol 54: 343-353.
24. Ling YH, Liebes L, Zou Y, Perez-Soler R, (2003) Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 278: 33714-33723.
25. Edelman MJ, (2005) The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer. Clin Lung Cancer 7Suppl 2: S64-66.
26. Hall EJ, Giaccia AJ (2012) Radiobiology for the radiologist. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. ix, 546 p.
27. Vakifahmetoglu H, Olsson M, Zhivotovsky B, (2008) Death through a tragedy: mitotic catastrophe. Cell Death Differ 15: 1153-1162.
28. Weinstock DM, Nakanishi K, Helgadottir HR, Jasin M, (2006) Assaying double-strand break repair pathway choice in mammalian cells using a targeted endonuclease or the RAG recombinase. Methods Enzymol 409: 524-540.
29. Jacquemont C, Taniguchi T, (2007) Proteasome function is required for DNA damage response and fanconi anemia pathway activation. Cancer Res 67: 7395-7405.
30. Murakawa Y, Sonoda E, Barber LJ, Zeng W, Yokomori K, et al. (2007) Inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells. Cancer Res 67: 8536-8543.
31. Neri P, Ren L, Gratton K, Stebner E, Johnson J, et al. (2011) Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors. Blood 118: 6368-6379.
32. Haaf T, Golub EI, Reddy G, Radding CM, Ward DC, (1995) Nuclear foci of mammalian Rad51 recombination protein in somatic cells after DNA damage and its localization in synaptonemal complexes. Proc Natl Acad Sci U S A 92: 2298-2302.
33. Yarde DN, Oliveira V, Mathews L, Wang X, Villagra A, et al. (2009) Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Res 69: 9367-9375.
34. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, et al. (2002) NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277: 16639-16647.
35. Perkins ND, (2012) The diverse and complex roles of NF-kappaB subunits in cancer. Nat Rev Cancer 12: 121-132.
36. Juvekar A, Manna S, Ramaswami S, Chang TP, Vu HY, et al. (2011) Bortezomib induces nuclear translocation of IkappaBalpha resulting in gene-specific suppression of NF-kappaB-dependent transcription and induction of apoptosis in CTCL. Mol Cancer Res 9: 183-194.
37. Williamson MJ, Silva MD, Terkelsen J, Robertson R, Yu L, et al. (2009) The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models. Mol Cancer Ther 8: 3234-3243.
38. Ngwa W, Tsiamas P, Zygmanski P, Makrigiorgos GM, Berbeco RI, (2012) A multipurpose quality assurance phantom for the small animal radiation research platform (SARRP). Phys Med Biol 57: 2575-2586.
39. Wong J, Armour E, Kazanzides P, Iordachita I, Tryggestad E, et al. (2008) High-resolution, small animal radiation research platform with x-ray tomographic guidance capabilities. Int J Radiat Oncol Biol Phys 71: 1591-1599.
40. Xue W, Meylan E, Oliver TG, Feldser DM, Winslow MM, et al. (2011) Response and resistance to NF-kappaB inhibitors in mouse models of lung adenocarcinoma. Cancer Discov 1: 236-247.
41. Russo A, Fratto ME, Bazan V, Schiro V, Agnese V, et al. (2007) Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence. Expert Opin Ther Targets 11: 1571-1586.
42. Stuschke M, Sak A, Wurm R, Sinn B, Wolf G, et al. (2002) Radiation-induced apoptosis in human non-small-cell lung cancer cell lines is secondary to cell-cycle progression beyond the G2-phase checkpoint. Int J Radiat Biol 78: 807-819.
43. Gabizon A, Martin F, (1997) Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 54Suppl 4: 15-21.
44. Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, et al. (2012) Proteasome inhibitors in multiple myeloma: 10 years later. Blood 120: 947-959.
45. Edelman MJ, Burrows W, Krasna MJ, Bedor M, Smith R, et al. (2010) Phase I trial of carboplatin/paclitaxel/bortezomib and concurrent radiotherapy followed by surgical resection in Stage III non-small cell lung cancer. Lung Cancer 68: 84-88.
46. Allen AM, Mentzer SJ, Yeap BY, Soto R, Baldini EH, et al. (2008) Pneumonectomy after chemoradiation: the Dana-Farber Cancer Institute/Brigham and Women's Hospital experience. Cancer 112: 1106-1113.
47. Albain KS, Swann RS, Rusch VW, Turrisi AT, (2009) Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 374: 379-386.
48. Qiao GB, Wu YL, Yang XN, Zhong WZ, Xie D, et al. (2005) High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. Br J Cancer 93: 137-143.
49. Saviozzi S, Ceppi P, Novello S, Ghio P, Lo Iacono M, et al. (2009) Non-small cell lung cancer exhibits transcript overexpression of genes associated with homologous recombination and DNA replication pathways. Cancer Res 69: 3390-3396.
50. Mansour WY, Schumacher S, Rosskopf R, Rhein T, Schmidt-Petersen F, et al. (2008) Hierarchy of nonhomologous end-joining, single-strand annealing and gene conversion at site-directed DNA double-strand breaks. Nucleic Acids Res 36: 4088-4098.
51. Bolstad BM, Irizarry RA, Astrand M, Speed TP, (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185-193.